JP2024532486A - Dll3を標的とする抗原認識受容体及びその使用 - Google Patents

Dll3を標的とする抗原認識受容体及びその使用 Download PDF

Info

Publication number
JP2024532486A
JP2024532486A JP2024513938A JP2024513938A JP2024532486A JP 2024532486 A JP2024532486 A JP 2024532486A JP 2024513938 A JP2024513938 A JP 2024513938A JP 2024513938 A JP2024513938 A JP 2024513938A JP 2024532486 A JP2024532486 A JP 2024532486A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532486A5 (cg-RX-API-DMAC10.html
Inventor
ジャネケ イー. ジャスパース,
マルジャン ザマン,
レニアー ジェイ. ブレントジェンズ,
Original Assignee
メモリアル スローン ケタリング キャンサー センター
スローン - ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, スローン - ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2024532486A publication Critical patent/JP2024532486A/ja
Publication of JP2024532486A5 publication Critical patent/JP2024532486A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024513938A 2021-09-02 2022-09-02 Dll3を標的とする抗原認識受容体及びその使用 Pending JP2024532486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240189P 2021-09-02 2021-09-02
US63/240,189 2021-09-02
PCT/US2022/042429 WO2023034555A1 (en) 2021-09-02 2022-09-02 Antigen recognizing receptors targeting dll3 and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532486A true JP2024532486A (ja) 2024-09-05
JP2024532486A5 JP2024532486A5 (cg-RX-API-DMAC10.html) 2025-09-10

Family

ID=85411573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513938A Pending JP2024532486A (ja) 2021-09-02 2022-09-02 Dll3を標的とする抗原認識受容体及びその使用

Country Status (7)

Country Link
US (1) US20240252640A1 (cg-RX-API-DMAC10.html)
EP (1) EP4396214A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024532486A (cg-RX-API-DMAC10.html)
CN (1) CN118215675A (cg-RX-API-DMAC10.html)
AU (1) AU2022339815A1 (cg-RX-API-DMAC10.html)
CA (1) CA3230627A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023034555A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021008610A1 (en) * 2019-07-17 2021-01-21 Nanjing Legend Biotech Co., Ltd. Anti-dll3 chimeric antigen receptors and uses thereof
WO2021158850A1 (en) * 2020-02-05 2021-08-12 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors with cd28 mutations and use thereof
JP2021520788A (ja) * 2018-04-10 2021-08-26 アムジエン・インコーポレーテツド Dll3に対するキメラ受容体及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
MX2021010441A (es) * 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
MX2021012336A (es) * 2019-04-08 2021-11-12 Phanes Therapeutics Inc Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520788A (ja) * 2018-04-10 2021-08-26 アムジエン・インコーポレーテツド Dll3に対するキメラ受容体及びその使用方法
WO2021008610A1 (en) * 2019-07-17 2021-01-21 Nanjing Legend Biotech Co., Ltd. Anti-dll3 chimeric antigen receptors and uses thereof
WO2021158850A1 (en) * 2020-02-05 2021-08-12 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors with cd28 mutations and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADV CELL GENE THER., vol. 3:e84, https://doi.org/10.1002/acg2.84, JPN6026028650, 2020, pages 1 - 9, ISSN: 0005901547 *
MOLECULAR THERAPY, vol. 25, no. 7, JPN6026028652, 2017, pages 1467 - 1475, ISSN: 0005901548 *

Also Published As

Publication number Publication date
AU2022339815A1 (en) 2024-03-14
EP4396214A4 (en) 2025-11-05
CN118215675A (zh) 2024-06-18
WO2023034555A1 (en) 2023-03-09
US20240252640A1 (en) 2024-08-01
EP4396214A1 (en) 2024-07-10
CA3230627A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
US11535869B2 (en) CD8-specific antibody constructs and compositions thereof
US20230087125A1 (en) Chimeric antigen receptors targeting cd127 and use thereof
JP7698655B2 (ja) Cd28変異を有するキメラ抗原受容体およびその使用
US20220213211A1 (en) Antigen recognizing receptors targeting cd371 and uses thereof
IL293598A (en) Cells expressing c-kit mutations and uses thereof
US20240252640A1 (en) Antigen recognizing receptors targeting dll3 and uses thereof
EP4452298A2 (en) Cells expressing fas ligand and cflip polypeptides and uses thereof
US20240197879A1 (en) Antigen recognizing receptors targeting cd33 and uses thereof
US20240189426A1 (en) Chimeric receptors targeting muc16 and uses thereof
US20240350547A1 (en) Cells Expressing FAS Ligand Polypeptides and FAS Knockout and Uses Thereof
US20250332256A1 (en) Antigen-recognizing receptors targeting b7-h3 and uses thereof
US20260131000A1 (en) Antigen recognizing receptors targeting l1cam and uses thereof
WO2025085796A1 (en) Armored immunoresponsive cells targeting dll3 and uses thereof
WO2025255291A1 (en) Chimeric antigen receptors targeting mesothelin and use thereof
CN118369332A (zh) 靶向cd33的抗原识别受体和其用途
WO2025096493A1 (en) Biomarkers and uses thereof for treatment of cancer with cd19-targeted adoptive cell therapies
WO2022212430A1 (en) Antigen recognizing receptors targeting gd3 ganglioside and uses thereof
EA048610B1 (ru) Антиген-узнающие рецепторы, нацеленные на cd371, и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260706